MyoKardia is a clinical stage biopharmaceutical company that develops therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.